BPC-157 Use Rose 33-Fold Since 2020, Study Finds
An nference analysis of over 15 million medical records found 1,039 patients with documented BPC-157 use, with new users increasing 33-fold between 2020 and 2026 despite limited human safety data.
PepNews
Retatrutide ‘Triple-G’ Completes Phase 3 Trials, FDA Filing Expected Early 2027
Eli Lilly's triple-agonist obesity drug retatrutide has completed its core Phase 3 program, with an FDA submission projected as early as 2027.
Alabama Medical Board Prohibits Physicians From Using Non-FDA-Approved Peptides
Alabama's medical board has issued an explicit prohibition on physicians compounding, administering, or dispensing non-FDA-approved or research-grade peptides to patients.
DOJ Charges Two Indian Nationals in Counterfeit Ozempic Scheme
A federal grand jury in Florida charged two Indian nationals with smuggling counterfeit Ozempic sourced from China into U.S. distribution channels.
20 State AGs Warn on Chinese GLP-1 Suppliers, Fentanyl Links
A 20-state coalition led by Tennessee AG Skrmetti warned Secretary of State Rubio that Chinese GLP-1 suppliers may be tied to fentanyl precursor manufacturers.
FDA Panel Recommends Six Peptides for 503A Compounding List
FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A Bulks List, overriding agency staff on all six.
FDA Warns Empower Pharmacy Over GLP-1 Compounding Violations
FDA issued a warning letter to Empower Pharmacy for compounding tirzepatide and semaglutide under insanitary conditions, calling the products essentially copies of approved drugs.
Forbes Opinion: End Mass-Market GLP-1 Compounding As Shortage Ends
A Forbes opinion piece argues FDA should restrict mass-market compounded GLP-1 drugs as the shortage ends, citing a Fifth Circuit ruling on FDA authority.
FDA Warns Five Peptide Vendors: RUO Labels No Legal Shield
FDA issued five Warning Letters to online peptide vendors for unapproved drug sales. ArentFox Schiff analysis confirms RUO labeling offers no legal protection.
FDA Warns 30 Telehealth Firms Over Misleading Compounded GLP-1 Marketing
The FDA issued warning letters to 30 telehealth companies for false or misleading claims about compounded GLP-1 weight-loss drugs, signaling intensified enforcement.
